MedTrace Logo

Nurse-led High-flow Nasal Cannula Weaning Protocol in Pediatric Intensive Care Unit

NCT06621641 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2025-11-25

No results posted yet for this study

Summary

Bronchiolitis is a leading cause of pediatric hospital admissions. Despite its limited clinical benefits, the use of HFNC in children with bronchiolitis is increasing.

Previous studies using quality improvement (QI) methodologies have successfully reduced HFNC usage through weaning protocols and trials of standard oxygen therapy.

This study involves implementing an HFNC initiation and weaning protocol at Aydın Maternity and Children's Hospital, involving infants aged 1-24 months admitted with bronchiolitis.

Conditions

  • Bronchiolitis
  • Respiratory Failure (Pediatric Patients)
  • High Flow Nasal Cannula

Interventions

BEHAVIORAL

The new HFNC weaning protocol

Patients will be randomly assigned to two groups: one following the new HFNC weaning protocol and another using the standard care protocol. The new protocol includes stepwise flow reduction based on the patient's clinical stability and uses the Respiratory Assessment Scale (RAS) to monitor weaning progress. The protocol emphasizes a multidisciplinary approach involving pediatricians, nurses, and respiratory therapists, with consistent training and application of weaning criteria

Sponsors & Collaborators

  • Hamilton Medical AG

    collaborator INDUSTRY

  • Dr. Behcet Uz Children's Hospital

    lead OTHER

Principal Investigators

  • Hasan Agin, Prof.Dr. · Dr. Behcet Uz Children's Hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
1 Month
Max Age
24 Months
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-10-01
Primary Completion
2025-05-30
Completion
2025-06-30

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06621641 on ClinicalTrials.gov